Costunolide inhibits osteoclast differentiation by suppressing c-Fos transcriptional activity

Phytotherapy Research

Volumn 28, Issue 4, 2014, Pages 586-592

  Cheon, Yoon Hee ^a   Song, Mi Jin ^a   Kim, Ju Young ^a   Kwak, Seong Cheoul ^a   Park, Ju Ha ^a   Lee, Chang Hoon ^a   Kim, Jeong Joong ^a   Kim, Jung Young ^a   Choi, Min Kyu ^a   Oh, Jaemin ^a   Kim, Youn Chul ^a   Yoon, Kwon Ha ^a   Kwak, Han Bok ^a   Lee, Myeung Su ^a  

^a Wonkwang University   (South Korea)

Author keywords

c Fos; costunolide; osteoclast; osteoporosis; sesquiterpene lactone

Indexed keywords

COSTUNOLIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SPECIFICITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

C-FOS; COSTUNOLIDE; OSTEOCLAST; OSTEOPOROSIS; SESQUITERPENE LACTONE;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; SESQUITERPENES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84898012610     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5034     Document Type: Article

References (32)

1. Asagiri M, Sato K, Usami T, et al,. 2005. Autoamplication of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202: 1261-1269.
2. Boyle WJ, Simonet WS, Lacey DL,. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
3. Carlisi D, D'Anneo A, Angileri L, et al,. 2011. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226: 1632-1641.
4. Chen HC, Chou CK, Lee SD, Wang JC, Yeh SF,. 1995. Active compounds from Saussurea lappa Clarks that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells. Antiviral Res 27: 99-109.
5. Gopal YN, Arora TS, Van Dyke MW,. 2007. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 14: 813-823.
6. Harada S, Rodan GA,. 2003. Control of osteoblast fuction and regulation of bone mass. Nature 423: 349-355.
7. Ichikawa H, Nair MS, Takada Y, et al,. 2006. Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression. Clin Cancer Res 1: 5910-5918.
8. Jang S, Bak EJ, Kim M, et al,. 2010. Wogonin inhibits osteoclast formation induced by lipopolysaccharide. Phytother Res 24: 964-968.
9. Kang JS, Yoon YD, Lee KH, Park SK, Kim HM,. 2004. Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells. Biochem Biophys Res Commun 313: 171-177.
10. Kassuya CA, Cremoneze A, Barros LF, et al,. 2009. Antipyretic and anti-inflammatory properties of the ethanolic extract, dichloromethane fraction and costunolide from Magnolia ovate (Magnoliaceae). J Ethnopharmacol 124: 369-376.
11. Kim JH, Yang YI, Lee KT, Park HJ, Choi JH,. 2011. Costunolide induces apotosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull 34: 580-585.
12. Kim K, Kim JH, Lee J, et al,. 2005. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280: 35209-35216.
13. Kreuger MR, Grootjans S, Biavatti MW, Vandenabeele P, D'Herde K,. 2012. Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide. Anticancer Drugs 23: 883-896.
14. Kwak HB, Lee BK, Oh J, et al,. 2010. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46: 724-731.
15. Lee YS, Choi EM,. 2011. Costunolide stimulates the function of osteoblastic MC3T3-E1 cells. Int Immunopharmacol 11: 712-718.
16. Mathema VB, Koh YS, Thakuri BC, Sillanpaa M,. 2012. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 35: 560-565.
17. Matsuo K, Galson DL, Zhao C, et al,. 2004. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279: 26475-26780.
18. Merfort I,. 2011. Perspectives on sesquiterpene lactones in inflammation and cancer. Curr Drug Targets 12: 1560-1573.
19. Moon HJ, Kim EK, Nam YS, et al,. 2012. Safflower seed extract inhibits osteoclast differentiation by suppression of the p38 mitogen-activated protein kinase and IκB kinase activity. Phytother Res 26: 1648-1655.
20. Rodan GA, Martin TJ,. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514.
21. Reddy DM, Qazi NA, Sawant SD, et al,. 2011. Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents. Eur J Med Chem 46: 3210-3217.
22. Srivastava SK, Abraham A, Bhat B, et al,. 2006. Synthesis of 13-amino costunolide derivatives as anticancer agents. Bioor Med Chem Lett 16: 4195-4199.
23. Takayanagi H, Kim S, Koga T, et al,. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
24. Takayanagi H,. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83: 170-179.
25. Takayanagi H,. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
26. Tanaka S, Nakamura K, Takahasi N, Suda T,. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208: 30-49.
27. Teitelbaum SL,. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
28. Teitelbaum SL, Ross FP,. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649.
29. Wang C, Duan H, He L,. 2009. Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol 612: 143-152.
30. Yamashita T, Yao Z, Li F, et al,. 2007. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282: 18245-18253.
31. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J,. 2004. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 19: 1905-1916.
32. Zidorn C,. 2008. Sesquiterpene lactones and their precursors as chemosystematic markers in the tribe Cichorieae of the Asteraceae. Phytochemistry 69: 2270-2296.